Loading clinical trials...
Loading clinical trials...
A Randomised Double-Blind, Double-Dummy, Placebo-Controlled, Stratified, Parallel-Group, Multicentre, Dose Ranging Study to Evaluate the Efficacy and Safety of GSK2190915 Tablets Administered Once Daily, Fluticasone Propionate Inhalation Powder 100mcg Twice Daily and Montelukast 10mg Once Daily Compared With Placebo for 8 Weeks in Adolescent and Adult Subjects With Persistent Asthma While Treated With Short Acting Beta2-agonist.
Conditions
Interventions
Fluticasone Propionate 100mcg via ACCUHALER/DISKUS
GSK2190915 100mg
+8 more
Locations
84
United States
GSK Investigational Site
Birmingham, Alabama, United States
GSK Investigational Site
Huntington Beach, California, United States
GSK Investigational Site
Newport Beach, California, United States
GSK Investigational Site
San Diego, California, United States
GSK Investigational Site
Tallahassee, Florida, United States
GSK Investigational Site
Owensboro, Kentucky, United States
Start Date
June 28, 2010
Primary Completion Date
October 6, 2011
Completion Date
October 6, 2011
Last Updated
October 2, 2017
NCT06979323
NCT07431021
NCT06664619
NCT07383896
NCT06003569
NCT07356310
Lead Sponsor
GlaxoSmithKline
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions